Alkermes presents new data from psychiatry portfolio at virtual 2021 Congress of the Schizophrenia International Research Society.

Alkermes plc announced the presentation of new research from its psychiatry portfolio at the 2021 Congress of the Schizophrenia International Research Society (SIRS), taking place virtually April 17-21, 2021. The company's presentations included new exploratory analyses from the phase III ENLIGHTEN-2 study of olanzapine/samidorphan (Lybalvi), formerly referred to as ALKS 3831, including: i. Results from prespecified subgroup analyses evaluating olanzapine/samidorphan's effect on weight gain across several patient subgroups, including those known to be at higher risk for weight gain with olanzapine, based on sex, race, age and baseline body mass index (BMI). ii. New findings from post hoc analyses assessing the effects of olanzapine/samidorphan compared to olanzapine across multiple cardiometabolic risk factors, including blood pressure, BMI and metabolic syndrome. In addition, the company presented data from an exploratory analysis within the phase IIIb ALPINE (Aripiprazole Lauroxil and Paliperidone palmitate: INitiation Effectiveness) study for Aristida (aripiprazole lauroxil), evaluating the relationship between baseline handwriting kinematics and treatment response. Results suggest that handwriting kinematic measures may serve as a biomarker for anticipating response to antipsychotic treatment.